Glenmede Trust’s Pfizer PFE Stock Holding History

Glenmede Trust’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-59	Closed	-$9K	–	1243
2020 Q4	$9K	Buy	+59	New	+$2.16K	﹤0.01%	1170

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Glenmede Trust's PFE Position: Q2 2026 in Review

Glenmede Trust reduced its Pfizer (PFE) stake by 12% in Q2 2026, selling an estimated $2.84M and leaving 793,315 shares worth $19.1M. The position accounts for 0.08% of the portfolio, ranked #200.

Glenmede Trust first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $227M in Q3 2018. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Glenmede Trust held 793,315 shares of Pfizer worth $19.1M as of Q2 2026.
Glenmede Trust sold 108,717 Pfizer shares in Q2 2026, an estimated $2.84M.
Pfizer made up 0.08% of Glenmede Trust's portfolio in Q2 2026, its #200 holding.
Glenmede Trust first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
Glenmede Trust's Pfizer position peaked at $227M in Q3 2018.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.